ePrivacy and GPDR Cookie Consent management by TermsFeed Privacy Generator
José Luis Sánchez Menoyo

Dr. José Luis Sánchez Menoyo

Neurólogo

SITUACION LABORAL

Desde 2007, médico adjunto de Neurología en el Hospital de Galdakao-Usansolo. Servicio Vasco de Salud-Osakidetza. Responsable de la Unidad de enfermedades desmielinizantes desde 2009.

 

FORMACIÓN ACADÉMICA

1992. Licenciado en Medicina y cirugía. Universidad del Pais Vasco-UPV

1996. Médico Especialista en Neurología. Hospital Universitario de Cruces. Servicio Vasco de Salud-Osakidetza.

1996. Cursos de Doctorado en Neurociencias. Universidad del Pais Vasco-UPV

2010. Master en Neuroinmunología. Universidad Autónoma de Barcelona.

 

PUBLICACIONES

1: Le M, Malpas C, Sharmin S, Horáková D, Havrdova E, Trojano M, Izquierdo G, Eichau S, Ozakbas S, Lugaresi A, Prat A, Girard M, Duquette P, Larochelle C, Alroughani R, Bergamaschi R, Sola P, Ferraro D, Grammond P, Grand' Maison F, Terzi M, Boz C, Hupperts R, Butzkueven H, Pucci E, Granella F, Van Pesch V, Soysal A, Yamout BI, Lechner-Scott J, Spitaleri D, Ampapa R, Turkoglu R, Iuliano G, Ramo-Tello C, Sanchez-Menoyo JL, Sidhom Y, Gouider R, Shaygannejad V, Prevost J, Altintas A, Fragoso YD, McCombe PA, Petersen T, Slee M, Barnett MH, Vucic S, Van Der Walt A, Kalincik T. Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. Mult Scler. 2020 Jun 15:1352458520926955. doi: 10.1177/1352458520926955. Epub ahead of print. PMID: 32538713.

2: Zhou Y, Claflin SB, Stankovich J, van der Mei I, Simpson S Jr, Roxburgh RH, Kalincik T, Blizzard L, Lugaresi A, Alroughani R, Sajedi SA, Butzkueven H, Pucci E, Spitaleri D, Granella F, Cristiano E, Yamout B, Hughes S, Gouider R, Sánchez Menoyo JL, Olascoaga J, McGuigan C, Shaw C, Kermode AG, Kasa K, Al-Harbi T, Altintas A, Laureys G, Fragoso Y, Hardy TA, Csepany T, Sirbu CA, Decoo D, Sas A, Alvarez-Cermeño JC, Kotkata K, Millán-Pascual J, Taylor BV. Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotype. Mult Scler. 2019 Oct 31:1352458519881994. doi: 10.1177/1352458519881994. Epub ahead of print. PMID: 31668127.

3: Fambiatos A, Jokubaitis V, Horakova D, Kubala Havrdova E, Trojano M, Prat A, Girard M, Duquette P, Lugaresi A, Izquierdo G, Grand'Maison F, Grammond P, Sola P, Ferraro D, Alroughani R, Terzi M, Hupperts R, Boz C, Lechner-Scott J, Pucci E, Bergamaschi R, Van Pesch V, Ozakbas S, Granella F, Turkoglu R, Iuliano G, Spitaleri D, McCombe P, Solaro C, Slee M, Ampapa R, Soysal A, Petersen T, Sanchez-Menoyo JL, Verheul F, Prevost J, Sidhom Y, Van Wijmeersch B, Vucic S, Cristiano E, Saladino ML, Deri N, Barnett M, Olascoaga J, Moore F, Skibina O, Gray O, Fragoso Y, Yamout B, Shaw C, Singhal B, Shuey N, Hodgkinson S, Altintas A, Al-Harbi T, Csepany T, Taylor B, Hughes J, Jun JK, van der Walt A, Spelman T, Butzkueven H, Kalincik T. Risk of secondary progressive multiple sclerosis: A longitudinal study. Mult Scler. 2020 Jan;26(1):79-90. doi: 10.1177/1352458519868990. Epub 2019 Aug 9. PMID: 31397221.

4: Kalincik T, Kubala Havrdova E, Horakova D, Izquierdo G, Prat A, Girard M, Duquette P, Grammond P, Onofrj M, Lugaresi A, Ozakbas S, Kappos L, Kuhle J, Terzi M, Lechner-Scott J, Boz C, Grand'Maison F, Prevost J, Sola P, Ferraro D, Granella F, Trojano M, Bergamaschi R, Pucci E, Turkoglu R, McCombe PA, Pesch VV, Van Wijmeersch B, Solaro C, Ramo-Tello C, Slee M, Alroughani R, Yamout B, Shaygannejad V, Spitaleri D, Sánchez-Menoyo JL, Ampapa R, Hodgkinson S, Karabudak R, Butler E, Vucic S, Jokubaitis V, Spelman T, Butzkueven H. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. J Neurol Neurosurg Psychiatry. 2019 Apr;90(4):458-468. doi: 10.1136/jnnp-2018-319831. Epub 2019 Jan 13. PMID: 30636699.

5: Lorscheider J, Kuhle J, Izquierdo G, Lugaresi A, Havrdova E, Horakova D, Hupperts R, Duquette P, Girard M, Prat A, Grand'Maison F, Grammond P, Sola P, Ferraro D, Trojano M, Ramo-Tello C, Lechner-Scott J, Pucci E, Solaro C, Slee M, Van Pesch V, Sanchez Menoyo JL, van der Walt A, Butzkueven H, Kappos L, Kalincik T; MSBase Study Group. Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study. Eur J Neurol. 2019 Feb;26(2):363-370. doi: 10.1111/ene.13824. Epub 2018 Nov 2. Erratum in: Eur J Neurol. 2020 Jun;27(6):1096. PMID: 30298572.

6: Bocos-Portillo J, Sánchez-Menoyo JL, Beldarrain MG, Saralegui Prieto I, Ontañón Garcés JM, Dalmau J, García-Moncó JC. Acute disseminated encephalomyelitis: A rare autoimmune complication of herpes simplex encephalitis in the adult. Clin Neurol Neurosurg. 2018 Dec;175:47-49. doi: 10.1016/j.clineuro.2018.10.007. Epub 2018 Oct 9. PMID: 30336448.

7: Min M, Spelman T, Lugaresi A, Boz C, Spitaleri D, Pucci E, Grand'Maison F, Granella F, Izquierdo G, Butzkueven H, Sanchez-Menoyo JL, Barnett M, Girard M, Trojano M, Grammond P, Duquette P, Sola P, Alroughani R, Hupperts R, Vucic S, Kalincik T, Van Pesch V, Lechner-Scott J. Silent lesions on MRI imaging - Shifting goal posts for treatment decisions in multiple sclerosis. Mult Scler. 2018 Oct;24(12):1569-1577. doi: 10.1177/1352458518798147. Epub 2018 Sep 20. PMID: 30234431.

8: Fragoso YD, Spelman T, Boz C, Alroughani R, Lugaresi A, Vucic S, Butzkueven H, Terzi M, Havrdova E, Horakova D, Granella F, Olascoaga J, Sánchez-Menoyo JL, Pucci E, Barnett M, Brooks JBB, Haartsen J; Lymphopenia and Efficacy of Fingolimod MSBase sub-study Investigators. Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod. Mult Scler Relat Disord. 2018 Jan;19:105-108. doi: 10.1016/j.msard.2017.11.018. Epub 2017 Nov 22. PMID: 29182993.

9: Ruisanchez Nieva A, Sanchez Menoyo JL, Escalza Cortina I, Foncea Beti N, Gomez Beldarrain M, Garcia-Monco JC. Neuromyelitis optica spectrum disorder in the elderly associated with bronchiolitis obliterans organizing pneumonia. Neurol Clin Pract. 2017 Oct;7(5):404-406. doi: 10.1212/CPJ.0000000000000336. PMID: 29620080; PMCID: PMC5874452.

10: Lorscheider J, Jokubaitis VG, Spelman T, Izquierdo G, Lugaresi A, Havrdova E, Horakova D, Trojano M, Duquette P, Girard M, Prat A, Grand'Maison F, Grammond P, Pucci E, Boz C, Sola P, Ferraro D, Spitaleri D, Lechner-Scott J, Terzi M, Van Pesch V, Iuliano G, Bergamaschi R, Ramo-Tello C, Granella F, Oreja-Guevara C, Butzkueven H, Kalincik T; MSBase Study Group. Anti-inflammatory disease- modifying treatment and short-term disability progression in SPMS. Neurology. 2017 Sep 5;89(10):1050-1059. doi: 10.1212/WNL.0000000000004330. Epub 2017 Aug 9. PMID: 28794248; PMCID: PMC5589791.